Christine Blank, Contributing Editor
FDA clears second Remicade biosimilar
In what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).
FDA: Limit codeine and tramadol use in kids
FDA said this week that it is restricting the use of codeine and tramadol medicines in children. The drug’s labels will now include a contraindication that codeine should not be used to treat pain or cough, and that tramadol should not be used to treat pain, in children younger than 12 years.
CVS: Generics and Biosimilars Are Key to Its Drug Spending Decline
Drug spending is going down at CVS Caremark. Here’s why.
Many Health-Care Groups Laud Generics Bill
Nearly 20 health-care organizations and PBMs come out in favor of FAST Generics Act.
How Pill Bottles Can Deter Opioid Misuse and Abuse
How Pill Bottles Can Deter Opioid Misuse and Abuse
Special pill bottle caps can help reduce medication misuse and abuse.
Potential blockbuster arthritis drug delayed
Citing safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis.
Novel drug approved for Huntington's symptom
FDA recently approved deutetrabenazine (Austedo, Teva Pharmaceuticals) to treat chorea associated with Huntington’s disease (HD). The medication is only the second product approved to treat HD, and is the first deuterated product approved by FDA.
Hep C drugs approved for kids
FDA approved supplemental applications for 2 primary hepatitis C medications to be used in children for the first time.
Pharmacists Are Central to Supervalu Diabetes Campaign
Supervalu’s diabetes campaign offers risk assessments, screening, and food education.
Study: New Diabetes Drug Class Reduces Heart Deaths
New class of glucose-lowering agents lowers hospitalization and death rates even in Type 2 patients without heart disease.

Poll

View Results